Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey

Sequential endocrine therapy (ET) is recommended for postmenopausal women with hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2−) metastatic breast cancer (mBC) and without visceral symptoms. Chemotherapy (CT) can be considered after sequential ETs, but is asso...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Lin, Peggy L., Hao, Yanni, Xie, Jipan, Li, Nanxin, Zhong, Yichen, Zhou, Zhou, Signorovitch, James E., Wu, Eric Q.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735772/
https://ncbi.nlm.nih.gov/pubmed/26686532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.580
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars